{"filings":[{"id":95081,"accession_number":"0001104659-26-044093","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Acurx raises ~$2.5M in registered direct offering plus up to $4.6M from warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 825,085 shares (or pre-funded warrants) at $3.03/share for ~$2.5M gross proceeds.","Concurrent private placement of 1,650,170 Series H warrants at $2.78/share, exercisable for 24 months.","Potential additional gross proceeds of ~$4.6M if short-term warrants fully exercised on cash basis.","Proceeds to be used for working capital and general corporate purposes.","H.C. Wainwright & Co. acted as exclusive placement agent; fees 6.0% of gross proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107893,"accession_number":"0001104659-26-025003","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Acurx launches ibezapolstat pilot trial in recurrent CDI; Phase 2 showed 96% cure, no recurrence","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO, Executive Chairman, CFO take 10% base salary cut; director cash retainers also reduced 10%, effective April 1, 2026.","Acurx opens open-label pilot trial for ibezapolstat in multiply-recurrent CDI (up to 20 patients); first enrollment expected Q4 2026.","Phase 2 data: ibezapolstat achieved 96% clinical cure (25/26) and 100% sustained cure with no recurrence at 1 month (25/25).","Beneficial gut microbiome preservation and bile acid data suggest potential for single-agent treatment and prevention of rCDI.","Company plans to seek FDA approval under LPAD pathway for rCDI treatment and prevention after Phase 3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140984,"accession_number":"0001104659-25-092166","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2025-09-22T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Acurx increases authorized common stock from 200 million to 250 million shares","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved amendment at special meeting on September 16, 2025.","Authorized common stock increased from 200,000,000 to 250,000,000 shares.","Amendment filed with Delaware Secretary of State on September 22, 2025, effective immediately.","Shares may be used for future capital raising, acquisitions, or other corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140983,"accession_number":"0001104659-25-091733","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2025-09-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Acurx shareholders approve warrant exercise and authorized share increase at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal 1 (warrant exercise for Nasdaq compliance): 8,816,581 for, 602,155 against, 9,823,429 broker non-votes.","Proposal 2 (authorized share increase 200M to 250M): 16,476,460 for, 2,526,119 against, 363,000 abstentions.","Proposal 3 (adjournment) approved: 16,538,163 for, 2,271,234 against, 556,182 abstentions.","Quorum: 19,365,579 shares (63.44%) of 30,524,540 outstanding shares represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140982,"accession_number":"0001104659-25-072529","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Acurx Pharmaceuticals announces 1-for-20 reverse stock split effective August 4, 2025 to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio 1-for-20; effective 4:01 p.m. ET on August 4, 2025.","Post-split trading begins August 5, 2025 under ticker ACXP; new CUSIP 00510M 203.","Outstanding shares reduced from ~30.8M to ~1.5M; authorized shares unchanged.","Fractional shares paid in cash based on August 1, 2025 closing price.","Split approved by stockholders at July 17, 2025 annual meeting; intended to regain Nasdaq minimum bid price compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140981,"accession_number":"0001104659-25-068659","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2025-07-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Acurx shareholders approve reverse split, equity plan increase, and director elections at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All six proposals passed at July 17 meeting; 74.38% of shares represented.","Reverse stock split authorized at ratio 1:10 to 1:30; board to set timing and exact ratio.","2021 Equity Plan share reserve increased from 177,448 to 2,677,448 shares.","Directors Sailer and Harrison re-elected; auditor CohnReznick ratified; warrant exercise and ELOC approved for Nasdaq compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158750,"accession_number":"0001104659-25-060902","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Acurx Pharma raises $2.67M via warrant exercise; issues new warrants for ~8.89M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered warrant inducement agreement; holder exercised ~4.45M existing warrants at reduced $0.60/share, gross proceeds $2.67M.","Net proceeds ~$2.3M after fees; used for working capital and general corporate purposes.","Issued new G-1 and G-2 warrants to purchase up to 8,890,870 shares at $0.425/share; G-1 exercisable immediately, G-2 upon shareholder approval.","H.C. Wainwright gets 7% fee and warrants to purchase 266,726 shares at $0.75/share.","Expected close June 20, 2025; 45-day stock issuance restriction and 90-day variable rate transaction restriction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158749,"accession_number":"0001104659-25-047566","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acurx Q1 net loss narrows to $2.1M ($0.11/sh); cash $4.6M; EMA guidance for ibezapolstat Phase 3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.1M ($0.11 diluted EPS) vs $4.4M ($0.28) Q1 2024; R&D fell to $0.6M, G&A to $1.6M.","Cash $4.6M at March 31, 2025, up from $3.7M at year-end 2024 after two offerings raising ~$3.6M gross.","Closed $2.5M registered direct offering in Jan 2025 and $1.1M offering in Mar 2025; $12M Lincoln Park equity line closed in May.","Received positive EMA regulatory guidance for ibezapolstat Phase 3 program, aligned with FDA, confirming MAA pathway.","Japanese and Indian patent offices granted new DNA polymerase IIIC inhibitor patents expiring Dec 2039 for ACX-375C."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158748,"accession_number":"0001104659-25-046167","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Acurx Pharmaceuticals secures up to $12M equity line from Lincoln Park Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lincoln Park committed to purchase up to $12M in common stock over 24 months.","Regular purchases up to 60k shares/day (90k if stock ≥$2, 120k if ≥$3).","Purchase price set at 97% of lowest of day's low or avg of three lowest closes in prior 10 days.","Company issued 899,258 commitment shares to Lincoln Park as consideration.","Proceeds to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177151,"accession_number":"0001104659-25-029370","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Acurx Pharma receives Nasdaq notice for non-compliance with equity requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice based on 10-K for FY 2024; stockholders' equity fell below $2.5M minimum.","Company has 45 days (until May 9, 2025) to submit a Compliance Plan to Nasdaq.","If plan accepted, Nasdaq may grant up to 180-day extension to regain compliance.","If plan rejected, common stock subject to delisting; company can appeal to Hearing Panel.","Company cautions no assurance that plan will be accepted or compliance regained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177150,"accession_number":"0001104659-25-024731","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acurx Pharma reports FY 2024 net loss $14.1M; cash $3.7M; EMA guidance for Phase 3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2024 $2.8M ($0.16/diluted share) vs $5.1M ($0.37) in Q4 2023; FY 2024 net loss $14.1M ($0.87) vs $14.6M ($1.15).","Cash at Dec 31, 2024: $3.7M, down from $7.5M; raised $6.6M via ATM in 2024 plus $3.6M in direct offerings in early 2025.","Positive EMA guidance for ibezapolstat Phase 3 program aligned with FDA; regulatory pathway for MAA after Phase 3 completion.","Japan patent granted for DNA pol IIIC inhibitors (expires 2039); advancing ACX-375C for MRSA/VRE/Anthrax.","Phase 2 data: 96% clinical cure, 100% sustained cure at 1 month; non-clinical studies show microbiome-restorative potential."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177149,"accession_number":"0001104659-25-021978","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Acurx Pharmaceuticals raises $1.1M in registered direct offering and private warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Aggregate gross proceeds of ~$1.1M from 2.15M common shares and 595K pre-funded warrants at $0.40/share.","Private placement includes Series F warrants for up to 8.235M shares at $0.40, exercisable upon stockholder approval.","H.C. Wainwright exclusive placement agent; 7% cash fee plus warrants for 164,700 shares at $0.50.","Net proceeds to be used for working capital and general corporate purposes.","Offering expected to close on or about March 10, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177148,"accession_number":"0001104659-25-017437","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Acurx Pharmaceuticals receives Nasdaq minimum bid price deficiency notice; 180-day cure period","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stock closed below $1.00 for 31 consecutive business days, triggering Nasdaq Listing Rule 5550(a)(2) deficiency.","Company has until August 25, 2025 to regain compliance by closing at $1.00 or higher for 10 consecutive business days.","If compliance not met, Company may seek a second 180-day period via a reverse stock split if other listing standards are met.","No immediate effect on listing; stock continues trading on Nasdaq Capital Market under symbol 'ACXP'.","Company intends to monitor bid price and consider available options but can provide no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177147,"accession_number":"0001104659-25-001586","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Acurx Pharmaceuticals prices $2.5M registered direct offering of 2.46M shares at $1.015","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$2.5M from 2,463,058 shares at $1.015/share in registered direct offering.","Concurrent private placement of Series E warrants to buy up to 2,463,058 shares at $0.90, exercisable for 5 years.","Net proceeds to be used for working capital and general corporate purposes; closing expected Jan 7, 2025.","Placement agent H.C. Wainwright receives 7% cash fee and warrants for 147,783 shares at $1.2688.","Affiliate investors (including CEO and Executive Chairman) purchase 167,488 shares in the offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193933,"accession_number":"0001104659-24-117214","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acurx Pharma Q3 net loss $2.8M; cash $5.8M; advancing ibezapolstat Phase 3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.8M ($0.17/diluted share) vs $3.1M ($0.24) in Q3 2023; nine-month net loss $11.3M.","Cash $5.8M at Sep 30, 2024, down from $7.5M at Dec 31, 2023; raised $1.6M gross via ATM.","Requested FDA CMC meeting to start Phase 3 for ibezapolstat; USPTO patent granted through 2042.","R&D expenses $1.2M (Q3) vs $1.3M prior year; G&A $1.6M vs $1.8M prior year."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210261,"accession_number":"0001104659-24-087545","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acurx Q2 net loss $4.1M, cash $6.4M; FDA confirms Phase 3 readiness for ibezapolstat","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.1M ($0.26/diluted share) for Q2 2024 vs. $3.4M ($0.28) in Q2 2023.","Cash $6.4M at June 30, 2024, down from $7.5M at Dec 31, 2023; raised $0.3M via ATM in Q2.","R&D expenses $1.8M (Q2 2024) vs $1.7M (Q2 2023); G&A $2.3M vs $1.7M.","Completed End-of-Phase 2 FDA meeting; agreement on Phase 3 and NDA plan for ibezapolstat (IBZ) for C. difficile.","USPTO granted IBZ patent expiring June 2042 covering reduced recurrence and microbiome health."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228555,"accession_number":"0001104659-24-072270","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Acurx Pharmaceuticals announces results of annual shareholder meeting; directors elected, auditor ratified","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Quorum of 67.29% of outstanding shares (10,648,350 of 15,823,102) was present at June 17, 2024 Annual Meeting.","Class III directors Robert J. DeLuccia, Joseph C. Scodari, James Donohue re-elected with broker non-votes of 4,836,213 each.","Ratification of CohnReznick LLP as independent auditor for FY2024 passed with 10,542,955 votes for, 69,261 against, 36,134 abstentions.","All director nominees received majority of votes cast excluding broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228554,"accession_number":"0001104659-24-061579","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acurx Pharma Q1 net loss $4.4M; Phase 2b data positive, FDA agrees on Phase 3 plan","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.4M ($0.28/diluted share) vs $2.9M loss in Q1 2023; R&D expenses $1.6M, G&A $2.8M.","Cash $8.9M at March 31, 2024; raised ~$4.4M gross via ATM sale of 1,121,793 shares in Q1.","Phase 2b ibezapolstat results: 94% eradication of fecal C. difficile at Day 3 vs 71% for vancomycin; preserved gut microbiome.","End of Phase 2 meeting with FDA in April 2024; agreement reached on Phase 3 program and NDA pathway.","EMA approved SME designation for Acurx, granting fee reductions and support for European marketing authorization."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247217,"accession_number":"0001104659-24-035556","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2024-03-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acurx reports Q4 net loss $5.1M; ibezapolstat Phase 2b shows 96% cure rate","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $5.1M ($0.37/shr); full year net loss $14.6M ($1.15/shr).","Year-end cash $7.5M; subsequent ATM raised ~$4.5M.","Ibezapolstat Phase 2b: 96% clinical cure (25/26), 100% sustained cure at 30 days.","FDA End of Phase 2 meeting scheduled April 2024; Phase 3 plan to be discussed.","EMA granted SME designation; additional microbiome data positive vs vancomycin."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264651,"accession_number":"0001104659-23-118749","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2023-11-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Acurx Pharmaceuticals enters $17M ATM equity offering with A.G.P.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $17M of common stock may be sold from time to time in at-the-market offerings.","A.G.P./Alliance Global Partners acts as sales agent, receiving 3% of gross proceeds.","Sales may be made on Nasdaq Capital Market, OTC, or in negotiated transactions.","Company is not obligated to sell any shares under the agreement.","Offering made under existing Form S-3 shelf registration statement declared effective July 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264650,"accession_number":"0001104659-23-118064","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acurx reports Q3 net loss of $3.1M; ibezapolstat Phase 2 shows 96% cure rate, advancing to Phase 3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $3.1M ($0.24/diluted share) vs $3.5M ($0.32) in Q3 2022; cash $7.1M at Sept 30, 2023.","Post-quarter warrant conversion raised $2.2M via ~680,000 shares issued.","Ibezapolstat Phase 2 top-line: 96% (25/26) clinical cure rate at end of treatment; no safety concerns.","Company preparing for End-of-Phase 2 FDA meeting and Phase 3 initiation.","R&D expenses $1.3M in Q3 (down from $1.6M); G&A $1.8M (down from $2.0M)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264649,"accession_number":"0001104659-23-114274","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2023-11-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Acurx reports 96% clinical cure rate in Phase 2 trial of ibezapolstat for C. difficile infection","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["96% clinical cure rate (25/26 patients) in combined Phase 2a and 2b trials of ibezapolstat.","Ibezapolstat well tolerated; no drug-related serious adverse events; three mild GI events resolved.","Phase 2b vancomycin-controlled segment terminated early based on high observed cure rate.","Company plans End-of-Phase 2 FDA meeting in Q1 2024 and advancement to Phase 3.","Additional analyses of sustained cure, microbiome, and bile acids are forthcoming."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264648,"accession_number":"0001104659-23-105928","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2023-10-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Acurx discontinues Phase 2b ibezapolstat trial early on high cure rates, no safety concerns; Phase 3 accelerated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2b discontinued after blinded data showed high clinical cure rates for ibezapolstat and vancomycin, with no emerging safety concerns.","Company expects to advance ibezapolstat to Phase 3 more expeditiously; topline efficacy results to be reported promptly.","Ibezapolstat is first-in-class, FDA QIDP/Fast-Track-designated antibiotic for C. difficile infection, potentially first new antibiotic class in 30+ years.","Decision also influenced by site maintenance costs and slow enrollment due to COVID-19; Independent Data Monitoring Committee will not perform interim analysis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281882,"accession_number":"0001104659-23-090878","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acurx Pharma Q2 net loss widens to $3.4M; Phase 2b enrollment ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q2 2023: $3.4M ($0.28/sh) vs $2.6M ($0.26/sh) in Q2 2022.","Cash unchanged at $9.1M as of June 30, 2023; no revenue reported.","Phase 2b trial for ibezapolstat in C. difficile: 28 sites enrolling; 5 patients needed for interim IDMC review.","R&D expenses rose to $1.7M (Q2 2023) from $0.9M (Q2 2022) driven by Phase 2b costs.","CARB-X declined grant for ACX375C pre-clinical candidate; encouraged re-application."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300886,"accession_number":"0001104659-23-072936","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Acurx Pharmaceuticals stockholders approve officer exculpation amendment and reelect directors at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders elected David P. Luci and Jack H. Dean as Class II directors with 5,749,190 and 5,575,112 votes for, respectively.","Ratification of CohnReznick LLP as independent auditors for FY2023 approved with 9,016,668 votes for.","Amendment to Certificate of Incorporation to allow officer exculpation under Delaware law approved with 6,054,547 votes for.","Certificate of Amendment filed with Delaware Secretary of State on June 20, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300885,"accession_number":"0001104659-23-061848","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2023-05-17T23:59:59+00:00","items":["1.01","3.02","3.03","9.01"],"status":"ready","headline":"Acurx Pharma prices $4M registered direct offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$4M from sale of 1,333,333 shares (or pre-funded warrants) at $3.00 per share.","Concurrent private placement of Series C and D warrants to purchase up to 2,666,666 shares at $3.26, exercisable after 6 months.","Existing Series A and B warrants amended to extend expiry to May 18, 2029.","Offering expected to close May 18, 2023; Maxim Group LLC as placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320779,"accession_number":"0001104659-23-033054","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2023-03-16T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Acurx reports Q4/FY2022 net loss; Phase 2b CDI trial interim IDMC review at 36 patients","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $9.1M at Dec 31, 2022 vs $13.0M a year earlier.","Q4 net loss $3.3M ($0.28/share) vs $2.6M ($0.26); FY net loss $12.1M ($1.12) vs $12.7M ($1.49).","R&D expense FY2022 $4.8M (up from $2.0M) due to Phase 2b costs; G&A $7.3M (down from $10.8M).","Phase 2b CDI trial has enrolled 25 of 36 patients needed for IDMC interim review; IDMC may recommend early termination or continue enrollment.","Non-dilutive grant application for $11.3M for ACX-375 (MRSA) in final round; decision expected in April 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338907,"accession_number":"0001104659-22-117682","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acurx reports Q3 net loss of $3.5M; cash $10.6M; Phase 2b enrollment continues","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.5M ($0.32 per diluted share) for Q3 2022, vs $4.6M ($0.46) in Q3 2021.","Cash and cash equivalents $10.6M as of Sep 30, 2022, down from $13.0M at Dec 31, 2021.","Phase 2b trial for C. difficile infection enrollment ongoing; added sites, expecting up to 30 total.","Raised $4.225M in July 2022 via registered direct offering to institutional investor and executives.","R&D expenses $1.6M in Q3 2022 vs $1.1M in Q3 2021, increase due to Phase 2b costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356285,"accession_number":"0001104659-22-091225","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2022-08-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acurx reports Q2 2022 net loss of $2.6M; Phase 2b trial enrollment continues with site expansion","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.6M ($0.26/diluted) for Q2 2022 vs $4.0M ($0.57) a year ago.","Cash $9.1M at June 30, 2022, down from $13.1M at Dec 31, 2021.","Phase 2b CDI trial enrollment slower; up to 30 clinical sites being added.","Raised $4.225M via July 2022 direct offering to institutional investor and executives.","Ibezapolstat showed favorable killing kinetics vs vancomycin in lab studies."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356284,"accession_number":"0001104659-22-082266","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2022-07-25T23:59:59+00:00","items":["1.01","2.02","3.02","5.05","9.01"],"status":"ready","headline":"Acurx Pharmaceuticals raises $4.225M in registered direct offering; reports $9.1M cash","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$4.225M from sale of 1,289,980 shares/pre-funded warrants at $3.25 (institutional) and $3.80 (executives).","Concurrent private placement of Series A and B warrants to purchase up to 1,289,980 shares each; exercisable starting 6 months.","Preliminary cash and equivalents $9.1M as of June 30, 2022 (unaudited).","Board granted one-time waiver of Insider Trading Policy to let CEO, Executive Chairman, and director participate in the offering.","Net proceeds for general corporate purposes; closing expected July 27, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374664,"accession_number":"0001104659-22-068951","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2022-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Acurx shareholders elect directors and ratify auditor at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Carl V. Sailer elected with 3,743,543 votes for, 289,750 withheld; broker non-votes 1,656,180.","Thomas Harrison elected with 3,741,578 votes for, 291,715 withheld; broker non-votes 1,656,180.","Ratification of CohnReznick LLP as auditor: 5,584,342 for, 98,801 against, 6,330 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374663,"accession_number":"0001104659-22-058543","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2022-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acurx Pharma Q1 net loss $2.7M ($0.26/shr); Phase 2b CDI trial progressing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $11.1M at March 31, 2022, down from $13.0M at Dec 31, 2021.","Net loss $2.7M vs $1.5M YoY; R&D costs rose to $0.8M from $0.1M on Phase 2b trial costs.","Phase 2b CDI trial enrollment ongoing; completion expected late H2 2022.","Protocol amended to add exploratory Extended Clinical Cure endpoint at day 56 and day 84.","Shares outstanding 10,263,202 as of March 31, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393148,"accession_number":"0001104659-22-034747","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2022-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acurx reports Q4/FY2021 results; Phase 2b enrollment ongoing for ibezapolstat","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["R&D expense FY2021: $2.0M (vs $2.2M in 2020); Q4 2021: $0.7M (vs $0.5M).","G&A expense FY2021: $10.8M (vs $2.4M) due to stock-based compensation and professional fees.","Phase 2a trial for C. difficile infection achieved 100% clinical cure and sustained cure with ibezapolstat.","Phase 2b enrollment expected to complete in H2 2022, comparing ibezapolstat to vancomycin.","New microbiome study with University of Houston comparing ibezapolstat to other CDI antibiotics anticipated H2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":411615,"accession_number":"0001104659-21-139573","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2021-11-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acurx Pharma Q3 net loss $4.6M; Phase 2b enrollment underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.6M ($0.46/diluted share) for Q3 2021 vs. $1.3M ($0.21) in Q3 2020.","Cash balance $14.5M as of Sep 30, 2021; R&D spend $1.1M (up from $0.7M) on Phase 2b costs.","Phase 2b trial for C. difficile infection (ibezapolstat) enrollment started; completion expected Q3 2022.","Phase 2a data showed 100% clinical cure, 100% sustained cure, beneficial microbiome changes.","New collaboration with Leiden University to study DNA pol IIIC enzyme mechanism of action."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":430371,"accession_number":"0001104659-21-106315","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2021-08-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acurx Q2 2021 net loss $4.0M ($0.57/diluted share); IPO raised $17.25M gross","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.0M for Q2 2021 vs $0.9M loss in Q2 2020; R&D expenses down to $0.1M from $0.4M.","Cash balance $17.1M as of June 30, 2021, following June IPO gross proceeds of $17.25M including overallotment.","Health Holland awarded ~$500K grant to Leiden University to study DNA pol IIIC inhibitors in collaboration with Acurx.","Filed provisional patent for ibezapolstat to treat C. difficile infection with reduced recurrence and improved microbiome health.","SG&A expenses rose to $3.9M in Q2 2021 from $0.5M in Q2 2020, driven by stock-based compensation and professional fees."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}